InterCure to Acquire Leon Cannabis Pharmacy Chain, Issuing 1.75M-1.84M Shares

TL;DR

**InterCure is buying Leon Pharm, a major Israeli cannabis pharmacy, by issuing up to 1.84 million shares, boosting its market dominance.**

AI Summary

InterCure Ltd. (NASDAQ: INCR) announced on January 31, 2024, that it has signed a definitive agreement to acquire Leon Pharm Ltd., a prominent Israeli pharmacy chain specializing in medical cannabis. This acquisition will involve InterCure issuing between 1,755,000 and 1,845,000 of its shares to Leon Pharm's shareholders. This move is significant for investors because it expands InterCure's market share and distribution network in the rapidly growing Israeli medical cannabis sector, potentially boosting future revenue and solidifying its leadership position.

Why It Matters

This acquisition strengthens InterCure's position in the Israeli medical cannabis market by integrating a leading pharmacy chain, potentially increasing its revenue and market share. For investors, it means InterCure is expanding its operations and distribution, which could lead to long-term growth.

Risk Assessment

Risk Level: medium — The acquisition involves issuing a significant number of new shares, which could dilute existing shareholder value, and the success of the integration is not guaranteed.

Analyst Insight

A smart investor would view this acquisition as a strategic move to consolidate market leadership and expand distribution, suggesting a positive long-term outlook for InterCure. However, they should also monitor the impact of share dilution and the successful integration of Leon Pharm.

Key Numbers

• 1,755,000 — Minimum Shares Issued (The minimum number of InterCure shares to be issued to Leon Pharm shareholders as part of the acquisition.)
• 1,845,000 — Maximum Shares Issued (The maximum number of InterCure shares to be issued to Leon Pharm shareholders, depending on the share price at completion.)
• 1988 — Leon Pharm Establishment Year (The year Leon Pharm was established, indicating its long-standing presence in the market.)

Key Players & Entities

• InterCure Ltd. (company) — the acquiring company, a leading medical cannabis company
• Leon Pharm Ltd. (company) — the acquired company, a leading Israel-based pharmacy chain specializing in medical cannabis
• Amos Cohen (person) — Chief Financial Officer of InterCure Ltd.
• 1,755,000 (dollar_amount) — minimum number of shares InterCure will issue to Sellers
• 1,845,000 (dollar_amount) — maximum number of shares InterCure will issue to Sellers
• January 31, 2024 (date) — date of the press release and filing

Forward-Looking Statements

• InterCure's market share in the Israeli medical cannabis sector will increase significantly post-acquisition. (InterCure Ltd.) — high confidence, target: Q3 2024
• The issuance of new shares will lead to a slight dilution of existing shareholder value in the short term. (InterCure Ltd.) — medium confidence, target: Q2 2024
• InterCure's revenue from medical cannabis sales in Israel will see a noticeable boost in the next fiscal year. (InterCure Ltd.) — high confidence, target: FY 2025

FAQ

Filing Documents

• form6-k.htm (6-K) — 16KB
• ex99-1.htm (EX-99.1) — 15KB
• ex99-1_001.jpg (GRAPHIC) — 14KB
• 0001493152-24-004419.txt ( ) — 51KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Intercure Ltd. Date: January 31, 2024 By: /s/ Amos Cohen Amos Cohen Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR